Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Multiple Myeloma 4Lymphoma 3Recurrence 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell, Marginal Zone 2Glioma 2Glioblastoma 2Brain Neoplasms 2Solid Tumor 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Melanoma 1Leukemia 1Gliosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 29Bevacizumab 14Radiotherapy 12Trastuzumab 10Lomustine 9Capecitabine 8paclitaxel-Angiopep-2 conjugate 6Nivolumab 6pembrolizumab 5dabrafenib 5abemaciclib 5Radiation 5icotinib 4Surgical Procedures, Operative 4Paclitaxel 4Lapatinib 4Irinotecan 4Flucytosine 4Dianhydrogalactitol 4Corticotropin-Releasing Hormone 4Chlorotoxin 4Carboplatin 4vocimagene amiretrorepvec 3verubulin 3tucatinib 3osimertinib 3motexafin gadolinium 3XL647 3Spermine Synthase 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Brain Neoplasms × marizomib × Clear all
NCT02330562 2022-06-08

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

Celgene

Phase 1/2 Completed
121 enrolled 27 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT02903069 2021-04-19

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

Celgene

Phase 1 Completed
66 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡